4gqp
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4gqp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gqp OCA], [https://pdbe.org/4gqp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4gqp RCSB], [https://www.ebi.ac.uk/pdbsum/4gqp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4gqp ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4gqp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4gqp OCA], [https://pdbe.org/4gqp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4gqp RCSB], [https://www.ebi.ac.uk/pdbsum/4gqp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4gqp ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Methamphetamine (METH) abuse is a worldwide threat, without any FDA approved medications. Anti-METH IgGs and single chain fragments (scFvs) have shown efficacy in preclinical studies. Here we report affinity enhancement of an anti-METH scFv for METH and its active metabolite amphetamine (AMP), through the introduction of point mutations, rationally designed to optimize the shape and hydrophobicity of the antibody binding pocket. The binding affinity was measured using saturation binding technique. The mutant scFv-S93T showed 3.1 fold enhancement in affinity for METH and 26 fold for AMP. The scFv-I37M and scFv-Y34M mutants showed enhancement of 94, and 8 fold for AMP, respectively. Structural analysis of scFv-S93T:METH revealed that the substitution of Ser residue by Thr caused the expulsion of a water molecule from the cavity, creating a more hydrophobic environment for the binding that dramatically increases the affinities for METH and AMP. | ||
| + | |||
| + | Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.,Thakkar S, Nanaware-Kharade N, Celikel R, Peterson EC, Varughese KI Sci Rep. 2014 Jan 14;4:3673. doi: 10.1038/srep03673. PMID:24419156<ref>PMID:24419156</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 4gqp" style="background-color:#fffaf0;"></div> | ||
==See Also== | ==See Also== | ||
| Line 13: | Line 22: | ||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | *[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | ||
*[[3D structures of non-human antibody|3D structures of non-human antibody]] | *[[3D structures of non-human antibody|3D structures of non-human antibody]] | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
Current revision
Structure based design of sub-nanomolar affinity anti-methamphetamine single chain antibodies.
| |||||||||||
